Kyowa Hakko Kirin Pledges To Become Japan’s Top Biotech-based Pharma – Bio Japan
This article was originally published in PharmAsia News
YOKOHAMA, Japan - Yuzuru Matsuda, president and CEO of Kyowa Hakko Kirin Co., said his company aimed to become "the top-class global biotechnology-based pharma that does research and development in the area of life sciences out of Japan, continuously making innovative contributions with antibody drugs." Matsuda spoke to an audience at Bio Japan in Yokohama Oct. 17
You may also be interested in...
Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview with PharmAsia News (Part 2 of 2)
Tokyo-based Kirin Pharma, which plans to merge with Kyowa Hakko Oct. 1, has done some 35 partnerships since parent company Kirin Brewery entered the pharmaceutical business in 1982. Tamao Watanabe, Kirin Pharma's senior manager of business development for the licensing section in the business development department, recently sat down with PharmAsia News' Tokyo bureau to talk about its partnership with North Carolina-based biotech venture Argos Therapeutics and how to make Japan-Western biotech partnerships work.
TOKYO - The size of the up-front payment that Amgen provided Kyowa Hakko Kogyo this week to gain development and commercialization rights to the Phase I humanized monoclonal antibody KW-0761 for most of the world - except Japan, Korea, China and Taiwan - indicates strong interest in the Japanese company's Potelligent technology, experts say
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).